High Intensity Contact Ultrasound Interstitial Medical Device

Clinical Indications targeted by the SonoProbe

Given the neurosurgical specialty of Pr. Carpentier, the SonoProbe was designed to be used for the treatment of a range of indications in the brain: tumors, epileptic lesions, radiosurgery resistant metastases, meningiomas … with a net annual incidence in Europe and in the United States of more than 400,000 patients.

Due to its design, the SonoProbe can also be adapted for the treatment of diseases in other organs. It potentially can also be used for treatments in moving organs or in organs hidden by bony structures (liver, lung …)

Below, the two main stages of treatment of a brain tumor by the SonoProbe are described.


The SonoProbe treatment

The first step is diagnostic. It begins with local anesthesia and stereotactic insertion of the probe within the tumor. A biopsy is performed to determine the precise histological status of the tumor. In the same step, still under local anesthesia, the treatment can take place.





The second step is therapeutic. It happens within the MRI scanner. After verification by MRI of the exact positioning of the probe relative to the tumor, treatment planning is performed. The treatment can then begin, with continuous monitoring using MR images acquired in real-time. The treatment itself lasts between 5 and 15 minutes. At the end of the procedure, the patient is discharged from the MRI, the probe is removed, and the patient is able to leave the hospital (the same day).



  • unnamed-2

  • News CarThera

    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.